Download Files:
FNDR-20123
$380 – $2,850
Products Details
Product Description
– FNDR-20123 is a safe, first-in-class, and orally active anti-malarial HDAC inhibitor with IC50s of 31 nM and 3 nM for Plasmodium and human HDAC, respectively. FNDR-20123 exerts anti-malarial activity against Plasmodium falciparum asexual stage (IC50=41 nM) and sexual blood stage (IC50=190 nM for male gametocytes). FNDR-20123 inhibits HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8 (IC50=25/29/2/11/282 nM, respectively.) and inhibits Class III HDAC isoforms at nanomolar concentrations[1].
Web ID
– HY-131708A
Storage Temperature
– 4°C (Powder, sealed storage, away from moisture)
Shipping
– Room Temperature
Applications
– COVID-19-anti-virus
Molecular Formula
– C21H24ClN5O2
References
– [1]Potluri V, et al. Discovery of FNDR-20123, a histone deacetylase inhibitor for the treatment of Plasmodium falciparum malaria. Malar J. 2020;19(1):365. Published 2020 Oct 12.
CAS Number
– 2641930-61-0
Molecular Weight
– 413.90
Compound Purity
– 98.08
SMILES
– O=C(NO)C1=CC=C(CN2N=NC(C3=CC=C(CN4CCCC4)C=C3)=C2)C=C1.[H]Cl
Clinical Information
– No Development Reported
Research Area
– Infection
Solubility
– DMSO : 31.25 mg/mL (ultrasonic)
Target
– HDAC;Parasite
Isoform
– HDAC;HDAC1;HDAC2;HDAC3;HDAC6;HDAC8;Plasmodium
Pathway
– Anti-infection;Cell Cycle/DNA Damage;Epigenetics
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
